Author

Siyi Gu

ORCID 0000-0002-0711-7442Unclaimed ORCID profile · follow to get notified of new preprints

Additional preprints under this name without ORCID

Siyi Gu1 paper · Stanford University

Biology Disciplines

Click to filter author papers

Cell Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Organism:human· 1 Organism:mouse· 1 Organism:non-human primate· 1 Assay:protein structure· 1

Frequent Co-Authors

C. B. Collins· 1 shared Chris LangsdorfiD· 1 shared Christos M. KougentakisiD· 1 shared Cyra K. Fung· 1 shared Darin J. Hildebrandt· 1 shared Darrin A. Lindhout· 1 shared Diana LiiD· 1 shared Eric D. Turtle· 1 shared

Activity by Year

2025-2025 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCell Biology

C. B. Collins

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

Catalytic degradation of circulating targets with FcRn-mediated cycling LYTACs

Christos M. Kougentakis, Matthew J. Shurtleff, Rachel M. Lieser, Tao Chen, C. B. Collins, Isabel E. Johnson, Siyi Gu, Keith T. Akama, Kyle H. Doran, Cyra K. Fung, Darin J. Hildebrandt, Rozhan Khaleghi, Diana Li, Steve Rank, Thomas-Toan Tran, , Nicholas A. Lind

This paper introduces cataLYTACs, a new therapeutic modality that efficiently and durably degrades circulating proteins like IgE in vitro and in vivo, outperforming traditional inhibitors.

bioRxiv · Jan 12, 2025 · PreprintCell Biology